Ketone esters for aging T cells and inflammation in older adults
Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly
This will test whether taking a ketone ester can reduce senescent T cells and inflammation in healthy adults aged 65–80.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 65 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Harbin Medical University Academic / other |
| Locations | 1 site (Harbin, Heilongjiang) |
| Trial ID | NCT07087093 on ClinicalTrials.gov |
What this trial studies
This interventional study gives a ketone ester to healthy adults aged 65–80 and measures circulating senescent T lymphocytes and inflammatory markers before and after treatment. The trial is motivated by observations that beta-hydroxybutyrate levels fall with age and that ketone bodies have shown protective effects in animal models of cardiovascular and neurodegenerative disease. Participants must be free of chronic disease and meet liver, kidney, surgical, and medication-related eligibility criteria. All visits and dosing take place at the First Affiliated Hospital of Harbin Medical University in Harbin, Heilongjiang.
Who should consider this trial
Good fit: Healthy, ambulatory adults aged 65–80 without chronic disease, recent immunosuppressant or hormone use, major recent diet changes, or recent digestive surgery who can attend visits in Harbin are ideal candidates.
Not a fit: People with severe liver or kidney dysfunction, recent major digestive surgery, a history of cancer, or recent immunosuppressant or hormone use are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, this could lower age-related inflammation and point to a new preventive approach to reduce cardiovascular risk in older adults.
How similar studies have performed: Preclinical studies and some clinical work on ketone bodies suggest cardiovascular and neuroprotective benefits, but effects specifically on age-related T‑cell senescence and elderly cardiovascular disease remain largely untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age: 65\~80 years old. 2. The subjects are in good health, and no history of chronic diseases. Exclusion Criteria: 1. Have used immunosuppressants or hormone drugs in the past six months. 2. There has been a significant change in diet within the past month. 3. Having digestive tract surgery within one year. 4. Severe liver dysfunction (alanine aminotransferase level \> 3.0 upper limit of normal). 5. Severe kidney dysfunction (creatinine clearance rate \< 30 mL/min). 6. History of malignant tumor.
Where this trial is running
Harbin, Heilongjiang
- the First Affiliated Hospital, Harbin Medical University — Harbin, Heilongjiang, China (Recruiting)
Study contacts
- Study coordinator: Yue Li, Doctor
- Email: ly99ly@vip.163.com
- Phone: 86-451-85555673
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.